Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 121 participants.

Also called NCT05488431

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 121 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05488431
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05488431. Randomized; quadruple masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
Condition
Dyslipidemias
Condition
Cardiovascular Diseases
Condition
HIV Infections
Condition
Atherosclerosis
Intervention (Drug)
Bempedoic acid
Intervention (Other)
Placebo
Lead sponsor
Priscilla Hsue, MD (class: other)
Collaborator
University of California, Los Angeles (class: other)
Collaborator
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct05488431
Content hash
00ef8da46a80d956dc1b1e2b41581cd748cf17917fb8e615c015ac97c0553818